27/04/2023
🧬Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a 👨🔬developer of transdermal🩹 pharmaceutical products📦, announced financial and operational results📋 for the fiscal year ended January 31, 2023.
👇Here are some excerpts from the report:
💰Revenue for the year ended January 31, 2023, was $2.08 million, up 46% from 📊revenue of $1.4 million in fiscal year 2022. 📈Revenue growth was driven primarily by an increase🛒 in sales of contract manufacturing services by the Company’s wholly owned subsidiary, Pocono Pharmaceuticals.
⬇️ Read the full report - https://nutriband.com/nutriband-inc-reports-revenue-up-46-in-fiscal-2023/